Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian (Europe)
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian (Europe)
‘Tough, really tough’ : Ruben Amorim on his first year at Manchester United
30/10/2025
Kemi Badenoch smiles from the stump as she heads towards oblivion | John Crace
30/10/2025
A former Tory councillor tried to ban my novel Pigeon English. Why should pupils suffer because of him ?
30/10/2025
Prince and Princess of Wales win privacy case against Paris Match
30/10/2025
Breeders’ Cup 2025 : all-conquering O’Brien arrives with sights on new record
30/10/2025
Football Daily | Liverpool and Arne Slot get in on this whole ‘six-seven’ business
30/10/2025